History

PAION reports positive preclinical results of its substance Solulin in the indication haemophilia

PAION discontinues development of flovagatran

PAION's partner Acorda Therapeutics announces the start of the first phase I trial with GGF2 in patients with heart failure

PAION reports positive results of its short acting anaesthetic/sedative Remimazolam (CNS 7056) in a Phase IIb study

PAION expands Desmoteplase agreement with Lundbeck

PAION AG enters into an equity facility agreement for EUR 15 million

Filing of IND application for GGF2 in heart failure by PAION’s partner Acorda Therapeutics triggers first milestone payments

PAION's partner Ono Pharmaceutical starts clinical development activities with the anaesthetic/sedative CNS 7056 for the Japanese market

PAION's partner Lundbeck initiates Japanese clinical Phase II trial with Desmoteplase in ischaemic stroke

PAION discontinues development of CNS 5161 and terminates development co-operation with Ergomed

PAION successfully performs Phase Ib and Phase IIa trials with its anesthetic/sedative CNS 7056

PAION and ERGOMED report full data of CNS 5161 Phase IIa study in neuropathic cancer pain

PAION's novel sedative/anaesthetic CNS 7056 meets target profile in human proof of concept study (Phase I)

PAION's partner Lundbeck initiates new Phase III program with Desmoteplase for the treatment of ischaemic stroke (DIAS-3 and DIAS-4)

PAION conducts and successfully completes Phase I study with sedative/anestethic CNS 7056

PAION acquires CeNeS Pharmaceuticals plc and thereby adds the projects M6G, CNS 5161, CNS 7056 and GGF2 to its portfolio

PAION acquires world-wide rights to anticoagulant Flovagatran

PAION returns lincense for Enecadin

PAION's anticoagulant Solulin successfully tested in first-in-man study (proof of concept), SOLID-I

PAION agreement with Lundbeck comes into force, securing future Desmoteplase development and EUR 8 Million upfront-payment to PAION

PAION's partner Lundbeck decides to continue the development of Desmoteplase and also inlicenses the rights for the North-American territories.

Extended analysis of the DIAS-2 study data indicate that certain stroke patient subgroups may indeed benefit from Desmoteplase thus providing a rationale to continue the development.

PAION's partner Forest terminates the collaboration and returns Desmoteplase rights for North America.

Completion of the Phase III study with Desmoteplase (DIAS-2) in ischaemic stroke which at first leads to inconclusive results regarding the efficacy of Desmoteplase

Issue of 1 million share in a capital increase

Initiation of a development programme for a new generation of plasminogen activators

Startof the Phase II study TEST with Enecadin in Germany

PAION closes agreement with Lundbeck for the development and marketing of Desmoteplase in Europe, Japan and all countries outside USA and Canada

Initiation of the Phase III study with Desmoteplase (DIAS-2) in Europe, US, Canada and AustralAsia

Initial Public Offering of PAION stock

In-licensing of the neuroprotective Enecadin from Nippon Shinyaku

Completion of US Phase II study in stroke (DEDAS)

PAION closes agreement with Forest Inc. for the development and marketing of Desmoteplase in the North American markets

FDA grants Desmoteplase fast-track status

4th financing round of 9.8 million Euro

American Heart Association selects Desmoteplase as one of the top 10 advances in heart disease and stroke for 2003

3rd financing round of 8.4 million Euro

Successful completion of Phase II study in stroke (DIAS)

Return of PS-519 to Millennium due to financial constraints

In-licensing of PS-519 from Millennium

2nd financing round of 3.8 million Euro

First patient in first Desmoteplase Phase II study in ischaemic stroke (DIAS)

Founded in July 2000 (Founders: Dr. W. Soehngen, Dr. M. Soehngen; Co-Founders: Dr. F. Wirtz, Dr. A. Lamotte, Prof. W.-D. Schleuning)

Desmoteplase in-licensed from Schering AG

1st financing round of 28.6 million Euro